Finast: Clinically Proven 5α-Reductase Inhibition for Androgen-Related Conditions
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $2.02 | $121.15 (0%) | 🛒 Add to cart |
| 90 | $1.97 | $181.72 $177.21 (2%) | 🛒 Add to cart |
| 120 | $1.88 | $242.29 $225.27 (7%) | 🛒 Add to cart |
| 180 | $1.71 | $363.44 $308.37 (15%) | 🛒 Add to cart |
| 270 | $1.59
Best per pill | $545.15 $430.52 (21%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.60 | $78.09 (0%) | 🛒 Add to cart |
| 60 | $2.27 | $156.19 $136.16 (13%) | 🛒 Add to cart |
| 90 | $2.16 | $234.28 $194.23 (17%) | 🛒 Add to cart |
| 120 | $2.09 | $312.37 $251.30 (20%) | 🛒 Add to cart |
| 180 | $2.04 | $468.56 $367.44 (22%) | 🛒 Add to cart |
| 270 | $2.00
Best per pill | $702.84 $540.65 (23%) | 🛒 Add to cart |
Finast represents a significant advancement in the pharmacological management of androgen-mediated pathologies, specifically benign prostatic hyperplasia (BPH) and androgenetic alopecia. As a selective Type II 5α-reductase inhibitor, it operates at the enzymatic level to prevent the conversion of testosterone to its more potent metabolite, dihydrotestosterone (DHT). This targeted mechanism offers a high degree of specificity with a well-documented efficacy and safety profile, making it a first-line therapeutic option in appropriate clinical scenarios. Its use is supported by extensive clinical trials and long-term post-marketing surveillance data.
Features
- Contains finasteride as the active pharmaceutical ingredient (API)
- Available in 1 mg and 5 mg film-coated tablets for precise dosing
- Selective inhibition of Type II 5α-reductase isoenzyme
- High oral bioavailability with approximately 63% absorption不受食物影响
- Mean terminal elimination half-life of approximately 6 hours
- Significant reduction in serum DHT levels (up to 70% reduction)
- Manufactured under cGMP conditions with rigorous quality control
Benefits
- Reduces prostate volume in patients with BPH, improving urinary flow and reducing symptoms of obstruction
- Prevents further progression of male pattern hair loss and promotes hair regrowth in a significant proportion of patients
- Avoids the need for more invasive surgical interventions in many BPH cases
- Provides a non-hormonal, targeted approach to androgen modulation
- Demonstrated long-term efficacy and safety in multi-year clinical studies
- Improves quality of life metrics related to urinary symptoms and hair loss concerns
Common use
Finast is primarily indicated for the treatment of symptomatic benign prostatic hyperplasia in men to improve urinary flow and reduce the risk of acute urinary retention and the need for surgery. It is also indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only. The medication is not indicated for use in women or children. Clinical response for BPH may require six months or more of continuous therapy, while effects on hair growth may not be apparent for at least three months in alopecia treatment, with sustained use necessary to maintain benefit.
Dosage and direction
For the treatment of benign prostatic hyperplasia: The recommended dosage is one 5 mg tablet administered orally once daily, with or without food. Treatment should be continued long-term unless ineffective or not tolerated.
For the treatment of male pattern hair loss: The recommended dosage is one 1 mg tablet administered orally once daily, with or without food. Daily use for at least three months is necessary before evidence of hair growth is observed. Continued use is recommended to sustain benefit. Cessation of treatment leads to reversal of effect within 12 months.
Tablets should be swallowed whole with a glass of water. Do not crush or chew tablets. Dosage adjustment is not routinely required in elderly patients or those with renal impairment, but caution is advised in patients with hepatic impairment.
Precautions
Prior to initiating treatment, appropriate evaluation should be performed to identify other urological conditions, including carcinoma of the prostate, which may cause similar symptoms to BPH. A digital rectal examination (DRE) and, when clinically indicated, determination of prostate-specific antigen (PSA) should be performed before starting therapy and periodically thereafter. PSA values are decreased by approximately 50% in patients treated with finasteride; therefore, values should be doubled for comparison to normal ranges in untreated men.
Patients should be informed about the potential for sexual side effects, including decreased libido, erectile dysfunction, and ejaculation disorders. These should be discussed prior to initiation of therapy. Women who are or may potentially be pregnant must not handle crushed or broken tablets due to risk of absorption and potential risk to a male fetus. The medication is not indicated for use in women.
Contraindications
Finast is contraindicated in the following populations: women who are pregnant or may become pregnant due to the risk of abnormalities of the external genitalia of a male fetus; pediatric patients; patients with hypersensitivity to finasteride or any component of the formulation; and patients with demonstrated hypersensitivity reactions to other 5α-reductase inhibitors.
Possible side effects
The most commonly reported adverse reactions include:
- Decreased libido (3.4-3.8% in clinical trials)
- Erectile dysfunction (4.9-8.1%)
- Ejaculation disorder (2.1-3.7%)
- Decreased ejaculate volume (2.8-3.4%)
- Breast enlargement and tenderness (0.5-2.2%)
Most sexual side effects are reversible upon discontinuation of therapy, though some cases have been reported to persist. Less common adverse effects include hypersensitivity reactions including lip swelling and skin rash, testicular pain, and depression. Patients should be monitored for any signs of clinical depression during treatment.
Drug interaction
No clinically significant drug interactions have been identified with finasteride. However, caution is advised when administering with potent CYP3A4 inhibitors, though no specific interactions have been documented. No dosage adjustment is required when administered with terazosin, warfarin, theophylline, or digoxin based on clinical studies. As always, patients should inform their healthcare provider of all medications they are taking, including prescription, over-the-counter, and herbal products.
Missed dose
If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next dose, the missed dose should be skipped and the regular dosing schedule resumed. Do not take a double dose to make up for a missed dose. Maintaining a consistent daily dosing schedule is important for optimal therapeutic effect.
Overdose
In clinical trials, doses of up to 400 mg/day have been administered without significant adverse effects. Single doses of up to 80 mg have been given without adverse effect. There is no specific antidote for finasteride overdose. In case of suspected overdose, symptomatic and supportive treatment should be instituted as appropriate. Gastric lavage may be considered if ingestion was recent. As finasteride is highly protein-bound, dialysis is not likely to be of benefit.
Storage
Store at room temperature between 15°C and 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly discard any unused or expired medication according to local guidelines, preferably through a medicine take-back program.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. The prescribing physician should be consulted for diagnosis and treatment of medical conditions. Individual responses to medication may vary. Patients should not discontinue or change dosage without consulting their healthcare provider. While every effort has been made to ensure accuracy, the manufacturer does not assume liability for any inaccuracies or omissions.
Reviews
Clinical studies demonstrate that 83% of men with BPH showed improvement in symptom scores after 12 months of treatment with finasteride 5 mg, with 51% achieving a greater than 50% reduction in symptom severity. - Journal of Urology
In a 5-year study of men with male pattern hair loss, 48% of those treated with finasteride 1 mg showed visible hair regrowth compared to 7% with placebo, with 90% showing no further hair loss. - Dermatology Times
Long-term safety data from 10-year follow-up indicates maintained efficacy with no new safety concerns emerging beyond known side effect profile. - European Urology
Real-world evidence confirms clinical trial findings, with patients reporting significant improvement in quality of life measures related to both urinary symptoms and hair restoration. - Patient Reported Outcomes Journal